Anavex Life Sciences (AVXL) Research & Development (2016 - 2025)
Anavex Life Sciences recorded quarterly Research & Development of $4.7 million in Q4 2025, down 36.17% quarter-over-quarter from $7.3 million in Q3 2025, and down 55.43% year-over-year from $10.4 million in Q4 2024.
Anavex Life Sciences' Research & Development history runs 10 years deep, the most recent figure standing at $4.7 million for Q4 2025.
- In Q4 2025, Research & Development fell 55.43% year-over-year to $4.7 million; the TTM figure through Dec 2025 stood at $31.8 million (down 27.06% YoY), while the FY2025 annual figure was $37.6 million, down 10.15% from the prior year.
- Research & Development came in at $4.7 million for Q4 2025 at Anavex Life Sciences, down from $7.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $12.1 million in Q4 2022 to a low of $4.7 million in Q4 2025.
- A 5-year average of $9.5 million and a median of $9.8 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 53.53% in 2021 and sank 55.43% in 2025, its largest moves.
- Anavex Life Sciences' Research & Development stood at $8.7 million in 2021, then surged by 39.4% to $12.1 million in 2022, then fell by 28.04% to $8.7 million in 2023, then rose by 20.29% to $10.4 million in 2024, then tumbled by 55.43% to $4.7 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $4.7 million, $7.3 million, and $10.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 4.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.66 Mn |
| Sep 30, 2025 | 7.29 Mn |
| Jun 30, 2025 | 9.96 Mn |
| Mar 31, 2025 | 9.89 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Sep 30, 2024 | 11.61 Mn |
| Jun 30, 2024 | 11.81 Mn |
| Mar 31, 2024 | 9.73 Mn |
| Dec 31, 2023 | 8.68 Mn |
| Sep 30, 2023 | 10.06 Mn |
| Jun 30, 2023 | 10.28 Mn |
| Mar 31, 2023 | 11.31 Mn |
| Dec 31, 2022 | 12.07 Mn |
| Sep 30, 2022 | 11.38 Mn |
| Jun 30, 2022 | 9.27 Mn |
| Mar 31, 2022 | 8.60 Mn |
| Dec 31, 2021 | 8.66 Mn |
| Sep 30, 2021 | 9.37 Mn |
| Jun 30, 2021 | 8.96 Mn |
| Mar 31, 2021 | 6.72 Mn |
| Dec 31, 2020 | 7.93 Mn |
| Sep 30, 2020 | 6.10 Mn |
| Jun 30, 2020 | 6.73 Mn |
| Mar 31, 2020 | 6.05 Mn |
| Dec 31, 2019 | 6.35 Mn |
| Sep 30, 2019 | 4.71 Mn |
| Jun 30, 2019 | 5.76 Mn |
| Mar 31, 2019 | 6.08 Mn |
| Dec 31, 2018 | 5.71 Mn |
| Sep 30, 2018 | 4.41 Mn |
| Jun 30, 2018 | 3.00 Mn |
| Mar 31, 2018 | 3.25 Mn |
| Dec 31, 2017 | 2.69 Mn |
| Sep 30, 2017 | 3.84 Mn |
| Jun 30, 2017 | 2.30 Mn |
| Mar 31, 2017 | 2.49 Mn |
| Dec 31, 2016 | 2.04 Mn |
| Sep 30, 2016 | 3.37 Mn |
| Jun 30, 2016 | 1.16 Mn |